免疫治疗对肝癌患者术后细胞免疫功能的影响及临床疗效

目的 探讨肿瘤浸润性淋巴细胞（ＴＩＬ）、ｒＩＬ－２和环磷酰胺治疗对原发性肝细胞癌（ＨＣＣ）患者术后细胞免疫功能的影响和临床疗效。方法 对８例ＨＣＣ术后患者进行了ＴＩＬ、ｒｈ－２和环磷酰胺治疗,６例从肝动脉插管输入,２例从门静脉插管输入。结果 ＴＩＬ治疗后８例患者外周血自然杀伤细胞（ＮＫ）、ＩＬ－２治疗、Ｔ亚群及比率均有不同程度上升,差异有显著意义。ＴＮＦ、ＩＬ－６多有不同程度下降（Ｐ〉０．０５,Ｐ

Cellular immune function influence on postoperative patients with hepatocellular carcinoma and the clinical effect of TILs treatment

OBJECTIVE: To investigate the cellular immune function influence on postoperative patients with hepatocellular carcinoma (HCC) and clinical effect of TILs, rIL-2 and cyclophosphamide treatment. METHODS: Eight postoperative HCC patients were treated with TILs, rIL-2 and cyclophosphamide. Six patients were infused from the hepatic artery, and the other 2 infused from the portal vein. RESULTS: The IL-2 NK activity, Tsubsets, CD4(+)/CD8(+) level in the peripheral blood of all patients increased and the IL-6, TNF level of most patients decreased (P > 0.05, P < 0.01). For 6 - 18 month follow-up after management, 6 patients with radical tumor resection showed no recurrence. One patient having palliative resection showed no remnant tumor enlargement. One patient with increased TNF level for 8 IU died from hepatic failure 8 months after chemotherapy. CONCLUSIONS: The TILs, rIL-2 and cyclophosphamide treatment of postoperative HCC patients is effective in improving antitumorgenic immune function, preventing tumor recurrence, and restraining remnant tumor growth.